Patients with discordant responses to antiretroviral therapy have impaired killing of HIV-infected T cells

Sekar Natesampillai, Zilin Nie, Nathan W Cummins, Dirk Jochmans, Gary D. Bren, Jonathan B. Angel, Andrew David Badley

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

In medicine, understanding the pathophysiologic basis of exceptional circumstances has led to an enhanced understanding of biology. We have studied the circumstance of HIV-infected patients in whom antiretroviral therapy results in immunologic benefit, despite virologic failure. In such patients, two protease mutations, I54V and V82A, occur more frequently. Expressing HIV protease containing these mutations resulted in less cell death, caspase activation, and nuclear fragmentation than wild type (WT) HIV protease or HIV protease containing other mutations. The impaired induction of cell death was also associated with impaired cleavage of procaspase 8, a requisite event for HIV protease mediated cell death. Primary CD4 T cells expressing I54V or V82A protease underwent less cell death than with WT or other mutant proteases. Human T cells infected with HIV containing these mutations underwent less cell death and less Casp8p41 production than WT or HIV containing other protease mutations, despite similar degrees of viral replication. The reductions in cell death occurred both within infected cells, as well as in uninfected bystander cells. These data indicate that single point mutations within HIV protease which are selected in vivo can significantly impact the ability of HIV to kill CD4 T cells, while not impacting viral replication. Therefore, HIV protease regulates both HIV replication as well as HIV induced T cell depletion, the hallmark of HIV pathogenesis.

Original languageEnglish (US)
Article numbere1001213
JournalPLoS Pathogens
Volume6
Issue number11
DOIs
StatePublished - Nov 2010

Fingerprint

HIV Protease
HIV
Cell Death
T-Lymphocytes
Peptide Hydrolases
Mutation
Therapeutics
Caspase 8
Caspases
Point Mutation
Medicine

ASJC Scopus subject areas

  • Microbiology
  • Parasitology
  • Virology
  • Immunology
  • Genetics
  • Molecular Biology

Cite this

Patients with discordant responses to antiretroviral therapy have impaired killing of HIV-infected T cells. / Natesampillai, Sekar; Nie, Zilin; Cummins, Nathan W; Jochmans, Dirk; Bren, Gary D.; Angel, Jonathan B.; Badley, Andrew David.

In: PLoS Pathogens, Vol. 6, No. 11, e1001213, 11.2010.

Research output: Contribution to journalArticle

Natesampillai, Sekar ; Nie, Zilin ; Cummins, Nathan W ; Jochmans, Dirk ; Bren, Gary D. ; Angel, Jonathan B. ; Badley, Andrew David. / Patients with discordant responses to antiretroviral therapy have impaired killing of HIV-infected T cells. In: PLoS Pathogens. 2010 ; Vol. 6, No. 11.
@article{71b69d7965344bce9834fda7d8781d37,
title = "Patients with discordant responses to antiretroviral therapy have impaired killing of HIV-infected T cells",
abstract = "In medicine, understanding the pathophysiologic basis of exceptional circumstances has led to an enhanced understanding of biology. We have studied the circumstance of HIV-infected patients in whom antiretroviral therapy results in immunologic benefit, despite virologic failure. In such patients, two protease mutations, I54V and V82A, occur more frequently. Expressing HIV protease containing these mutations resulted in less cell death, caspase activation, and nuclear fragmentation than wild type (WT) HIV protease or HIV protease containing other mutations. The impaired induction of cell death was also associated with impaired cleavage of procaspase 8, a requisite event for HIV protease mediated cell death. Primary CD4 T cells expressing I54V or V82A protease underwent less cell death than with WT or other mutant proteases. Human T cells infected with HIV containing these mutations underwent less cell death and less Casp8p41 production than WT or HIV containing other protease mutations, despite similar degrees of viral replication. The reductions in cell death occurred both within infected cells, as well as in uninfected bystander cells. These data indicate that single point mutations within HIV protease which are selected in vivo can significantly impact the ability of HIV to kill CD4 T cells, while not impacting viral replication. Therefore, HIV protease regulates both HIV replication as well as HIV induced T cell depletion, the hallmark of HIV pathogenesis.",
author = "Sekar Natesampillai and Zilin Nie and Cummins, {Nathan W} and Dirk Jochmans and Bren, {Gary D.} and Angel, {Jonathan B.} and Badley, {Andrew David}",
year = "2010",
month = "11",
doi = "10.1371/journal.ppat.1001213",
language = "English (US)",
volume = "6",
journal = "PLoS Pathogens",
issn = "1553-7366",
publisher = "Public Library of Science",
number = "11",

}

TY - JOUR

T1 - Patients with discordant responses to antiretroviral therapy have impaired killing of HIV-infected T cells

AU - Natesampillai, Sekar

AU - Nie, Zilin

AU - Cummins, Nathan W

AU - Jochmans, Dirk

AU - Bren, Gary D.

AU - Angel, Jonathan B.

AU - Badley, Andrew David

PY - 2010/11

Y1 - 2010/11

N2 - In medicine, understanding the pathophysiologic basis of exceptional circumstances has led to an enhanced understanding of biology. We have studied the circumstance of HIV-infected patients in whom antiretroviral therapy results in immunologic benefit, despite virologic failure. In such patients, two protease mutations, I54V and V82A, occur more frequently. Expressing HIV protease containing these mutations resulted in less cell death, caspase activation, and nuclear fragmentation than wild type (WT) HIV protease or HIV protease containing other mutations. The impaired induction of cell death was also associated with impaired cleavage of procaspase 8, a requisite event for HIV protease mediated cell death. Primary CD4 T cells expressing I54V or V82A protease underwent less cell death than with WT or other mutant proteases. Human T cells infected with HIV containing these mutations underwent less cell death and less Casp8p41 production than WT or HIV containing other protease mutations, despite similar degrees of viral replication. The reductions in cell death occurred both within infected cells, as well as in uninfected bystander cells. These data indicate that single point mutations within HIV protease which are selected in vivo can significantly impact the ability of HIV to kill CD4 T cells, while not impacting viral replication. Therefore, HIV protease regulates both HIV replication as well as HIV induced T cell depletion, the hallmark of HIV pathogenesis.

AB - In medicine, understanding the pathophysiologic basis of exceptional circumstances has led to an enhanced understanding of biology. We have studied the circumstance of HIV-infected patients in whom antiretroviral therapy results in immunologic benefit, despite virologic failure. In such patients, two protease mutations, I54V and V82A, occur more frequently. Expressing HIV protease containing these mutations resulted in less cell death, caspase activation, and nuclear fragmentation than wild type (WT) HIV protease or HIV protease containing other mutations. The impaired induction of cell death was also associated with impaired cleavage of procaspase 8, a requisite event for HIV protease mediated cell death. Primary CD4 T cells expressing I54V or V82A protease underwent less cell death than with WT or other mutant proteases. Human T cells infected with HIV containing these mutations underwent less cell death and less Casp8p41 production than WT or HIV containing other protease mutations, despite similar degrees of viral replication. The reductions in cell death occurred both within infected cells, as well as in uninfected bystander cells. These data indicate that single point mutations within HIV protease which are selected in vivo can significantly impact the ability of HIV to kill CD4 T cells, while not impacting viral replication. Therefore, HIV protease regulates both HIV replication as well as HIV induced T cell depletion, the hallmark of HIV pathogenesis.

UR - http://www.scopus.com/inward/record.url?scp=79251523843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251523843&partnerID=8YFLogxK

U2 - 10.1371/journal.ppat.1001213

DO - 10.1371/journal.ppat.1001213

M3 - Article

C2 - 21124822

AN - SCOPUS:79251523843

VL - 6

JO - PLoS Pathogens

JF - PLoS Pathogens

SN - 1553-7366

IS - 11

M1 - e1001213

ER -